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ABSTRACT
The roles of GH and its receptor (GHR) in metabolic control are not
yet fully understood. We studied the roles of GH and the GHR using
the GHR antagonist pegvisomant for metabolic control of healthy
nonobese men in fasting and nonfasting conditions. Ten healthy sub-
jects were enrolled in a double blind, placebo-controlled study on the
effects of pegvisomant on GHRH and GH-releasing peptide-6 (GHRP-
6)-induced GH secretion before and after 3 days of fasting and under
nonfasting conditions (n 5 5). Under the condition of GHR blockade
by pegvisomant in the nonfasting state, GHRP-6 (1 mg/kg) caused a
increase in serum insulin (10.3 6 2.1 vs. 81.3 6 25.4 mU/L; P , 0.001)
and glucose (4.2 6 0.3 vs. 6.0 6 0.6 mmol/L; P , 0.05) concentrations.
In this group, a rapid decrease in serum free fatty acids levels was also
observed. These changes were not observed under GHR blockade
during fasting or in the absence of pegvisomant. We conclude that
although these results were obtained from an acute study, and long-
term administration of pegvisomant could render different results,
blockade of the GHR in the nonfasting state induces tissue-specific
changes in insulin sensitivity, resulting in an increase in glucose and
insulin levels (indicating insulin resistance of liver/muscle), but prob-
ably also in an increase in lipogenesis (indicating normal insulin
sensitivity of adipose tissue). These GHRP-6-mediated changes in-
dicate that low GH bioactivity on the tissue level can induce changes
in metabolic control, which are characterized by an increase in fat
mass and a decrease in lean body mass. As a mechanism of these
GHRP-6-mediated metabolic changes in the nonfasting state, direct
nonpituitary-mediated GHRP-6 effects on the gastroentero-hepatic
axis seem probable. (J Clin Endocrinol Metab 86: 590–593, 2001)
THE ROLES OF GH and its receptor (GHR) in the met-abolic control of man are not fully understood yet.
During fasting, serum GH levels increase significantly,
whereas serum total and free insulin-like growth factor I
(IGF-I) as well as insulin levels decline (1–3). Also, GH-
deficient (GHD) patients show, in parallel with acromegalic
patients with high GH concentrations, a reduction in insulin
sensitivity (4–6). In contrast to acromegalics, GHD patients
have an increase in fat mass (4, 6–8). Pegvisomant is a ge-
netically manipulated GH molecule that disables functional
dimerization of the two GH receptor (GHR) molecules in-
volved in signal transduction due to a single mutation at the
site II of the GH molecule. Pegvisomant is pegylated to
increase the serum half-life. Currently, the compound is used
in phase II and III trials for the treatment of acromegaly
(9–12). Pegvisomant potentially can also be used in studies
in normal individuals to obtain more insight into the role of
GH, its receptor, and its secretagogues in metabolic control.
We performed a double blind, placebo-controlled, cross-over
study comparing the effects of placebo vs. a single sc injection
of 80 mg pegvisomant on GHRH- and GH-releasing pep-
tide-6 (GHRP-6)-induced GH secretion both before and after
a 3-day period of fasting in 10 healthy young male subjects.
We also repeated the same study in 5 of the 10 subjects, but
under nonfasting conditions. During this open label study
period, all subjects received pegvisomant.
Subjects and Methods
Ten healthy male subjects, 20–30 yr of age (mean 6 sd age, 23.4 6 2.7
yr; range, 20–28), with a normal body weight (mean 6 sd body mass
index, 21.8 6 1.8 kg/m2; range, 19.7–25.8) were asked to participate.
None of the subjects had a relevant medical history or used medication.
All 10 subjects participated in the cross-study, and 5 of these 10 sub-
sequently participated in the single arm study (see below). The study
was approved by the local ethical committee and all subjects gave
written informed consent before enrolment in the study.
The study consisted of two parts: a double blind, placebo-controlled,
cross-over study comparing GHR blockade with placebo before and
after 3 days of fasting (with free access to noncaloric fluids), and a single
arm, open label study in which the effect of GHR blockade under
nonfasted conditions (continuation of subject’s normal daily diet) was
investigated. All study periods in both protocols lasted 4 days, during
which the subjects were admitted to the Clinical Research Unit (CRU).
Except for fasting, study periods in both protocols were identical. In the
fasting study all subjects had to fast from 2400 h on the day before
admission until after the first test. They were admitted to the CRU at
0730 h, at which time two indwelling iv catheters were inserted in both
forearms. On days 1 and 4, a GHRP-6 or GHRH test was performed
between 0800–0900 h. A second test (GHRH or GHRP-6 test) was per-
formed between 1600–1700 h (exactly 8 h after the first test). Between the
two tests, a standard light meal was served to all subjects on day 1, but
not to subjects in the fasting group on day 4. This light meal consisted
of two slices of bread, with one unit of butter, one slice of cheese, one
unit of fruit jelly, and one unit of milk (caloric content, 1764 kJ). Im-
mediately after the second GH stimulatory test either 80 mg Pegviso-
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mant or placebo were administered sc. All subjects fasted from midnight
on day 1 until the end of the study.
In the nonfasting arms of the study, all subjects also had to fast from
2400 h on the day before admission until after the first test. Again, they
were admitted to the CRU at 0730 h, at which time two indwelling iv
catheters were inserted in both forearms. On days 1 and 4, a GHRP-6 test
was performed between 0800–0900 h. A GHRH test was performed
exactly 8 h after the GHRP-6 test. Between the two tests, a standard light
meal, as described above, was served to all subjects on days 1 and 4.
Immediately after the GHRH test on day 1, 80 mg Pegvisomant were
administered sc. A wash-out period of at least 3 weeks was chosen in
between each of the admission periods for each subject. To detect
changes in concentrations over the day, blood samples for endocrine and
metabolic parameters were taken daily at intervals of 4 h throughout
every study period of 4 days. These samples were used to calculate mean
GH concentrations over the day.
GH stimulation tests
Either GHRH (Ferring Pharmaceuticals Ltd., Hoofddorp, The Neth-
erlands) or GHRP-6 (CLINALFA AG, Laufelingen, Switzerland) was
administered as an iv bolus injection of 1 mg/kg BW. Blood samples were
drawn every 15 min from 215 to 120 min after injection. In the cross-over
study, tests were performed in random order.
Study medication
GHR antagonist (Pegvisomant; Somavert) and placebo were supplied
by Sensus Drug Development Corp. (Austin, TX).
Assays
Samples were measured for endogenous GH in a two-site immuno-
assay that does not cross-react with pegvisomant. The interassay coef-
ficients of variation (CVs) are 4.1% at 4.0 mg/L and 3.8% at 20 mg/L. The
intraassay CVs are 3.4% at 0.25 mg/L, 1.9% at 2.5 mg/L, and 4.5% at 25
mg/L (Medical Klinik Innenstadt, Ludwig-Maximillians University,
Munich, Germany) (9). Serum IGF-I was determined using a commer-
cially available RIA (Biosource Technologies, Inc., Nivelles, Belgium;
intra- and interassay CVs, 5.0% and 9.6%, respectively). This IGF-I assay
measures IGF-I in acid-ethanol extracts. Free IGF-I concentrations were
assessed using a commercially available immunoradiometric assay (Di-
agnostics Systems Laboratories, Inc., Webster, TX; intra- and interassay
CVs, 10.3% and 10.7%, respectively). Glucose was determined with an
automatic hexokinase method (Roche, Almere, The Netherlands). In-
sulin was assessed by RIA (Medgenix Diagnostics, Brussels, Belgium;
intra- and interassay CVs, 13.7% and 8.0%, respectively). Free fatty acids
were determined with an enzymatic colorimetric method (Wako Chem-
icals GmbH, Neuss, Germany; intra- and interassay CVs, 1.1% and 4.1%,
respectively).
Statistical analysis
Means were compared with the Wilcoxon matched pairs test. All P
values are two-sided; P , 0.05 was considered significant. Unless oth-
erwise noted, all results are reported as the mean 6 sem. Analyses were
performed using Prism version 3.00 for Windows (GraphPad Software,




No significant differences were observed in serum GH
concentrations on day 1, expressed as the area under the
curve for all GH data obtained in 24 h, excluding GH con-
centrations that were obtained during the two stimulatory
tests. On day 4, however, serum GH concentrations increased
in all fasting subjects, whereas only in the fasting, pegviso-
mant-pretreated subjects was this increase in GH significant
(0.4 6 0.4 ng/mL on day 1 vs. 2.1 6 0.7 ng/mL on day 4).
Insulin
In Fig. 1A, serum insulin concentrations are shown on days
1 and 4 of each of the study periods. No significant changes
in serum insulin concentrations were observed after the ad-
ministration of 1 mg/kg GHRP-6. However, only in the pres-
ence of pegvisomant and in the nonfasting state was a rapid
and significant increase in insulin levels found (day 4; insu-
lin, 0800 h vs. 2400 h, 10.3 6 2.1 vs. 81.3 6 25.4 mU/L; P ,
0.001).
Glucose
No significant changes were observed in glucose after
GHRP-6 administration. Again, only in the presence of
pegvisomant and in the nonfasting state was a significant
increase in serum glucose levels observed (day 4; glucose,
0800 h vs. 2400 h, 4.2 6 0.3 vs. 6.0 6 0.6 mmol/L; P , 0.05;
Fig. 1B).
FIG. 1. Serum insulin (milliunits per L; A), serum glucose (millimoles
per L; B), and serum FFA (moles per L; C) concentrations after sc
administration of 1 mg GHRP-6 in normal healthy subjects with or
without fasting and with or without the presence of a GH blocker. f,
Fasting, placebo (n 5 10); , fasting, pegvisomant (n 5 10); F, non-
fasting, pegvisomant (n 5 5). All GHRP-6 tests were performed in all
subjects of all study groups (including the nonfasting group) after an
overnight fasting period. All subjects in the nonfasting group contin-
ued their normal daily diet throughout the study. Although different
symbols were used on day 1 for each study group, study conditions
with regard to fasting were identical for all subjects on this day.
Pegvisomant was administered only after the two stimulatory tests
were finished.
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Free fatty acids
Finally, only in the five nonfasting subjects and only in the
presence of pegvisomant was an acute and significant de-
crease in serum free fatty acid (FFA) levels observed (day 4;
FFA, 0800 h vs. 1600 h, 0.33 6 0.1 vs. 0.15 6 0.03 mmol/L; P ,
0.05). Interestingly, on day 4, FFA levels did increase after
GHRP-6 administration in the fasting state regardless of the
presence of a GHR blockade (0800 h vs. 1600 h, 0.89 6 0.01
vs. 1.30 6 0.18 mmol/L; P , 0.05; Fig. 1C). A decrease in
serum FFA concentrations in all groups was observed after
GHRP-6 administration on day 1.
IGF-I
Serum total IGF-I levels did not change during the fasting
period. However, we observed an increase in IGF-I levels on
day 2, which was probably induced by the two stimulatory tests
on day 1 (mean IGF-I at baseline, 26.6 6 2.6 nmol/L; at 1600 h
on day 2, 31.9 6 3.3 nmol/L). After day 2, total IGF-I levels
began to decrease, but this decrease did not reach the level of
significance on day 4. There was a slight, but significant, de-
crease during fasting in the presence of pegvisomant compared
with the IGF-I levels in controls on day 4 (controls 0800 h on day
4 vs. pegvisomant 0800 h on day 4, 27.9 6 4.0 vs. 23.6 6 4.2
nmol/L; P , 0.05). Furthermore, blockade of the GHR did
significantly reduce serum free IGF-I levels. This decrease was
not further influenced during fasting (day 1 0800 h vs. day 4
0800 h, 0.12 6 0.02 vs. 0.04 6 0.00 nmol/L).
None of these parameters changed after the administration
of 1 mg/kg GHRH (data not shown).
Discussion
In this study pegvisomant was used to study the roles of
GH and its receptor in the metabolic control of the fasting
status. To our surprise, we found that the administration of
a standard dose of 1 mg/kg GHRP-6 induced an acute and
significant increase in serum insulin and glucose and a sig-
nificant decrease in FFA levels in normal individuals pre-
treated with pegvisomant when not fasted. Moreover,
GHRP-6 administration caused a significant increase in FFA
in the fasting state regardless of the presence of a GHR
blockade. Why these changes were not observed after the
administration of GHRH is not clear. Possibly, the effects of
GHRH on metabolic processes are either not important or are
mainly mediated by GH action, which in this study was
reduced by pegvisomant and/or fasting. All of these GHRP-
6-mediated changes in insulin, glucose, and FFA concentra-
tions in the pegvisomant-pretreated, nonfasting group re-
turned to baseline values the next day (data not shown). The
decrease in serum FFA levels to normal nonfasting levels on
day 1 in all groups is probably caused by an exaggerated food
intake the night before admission, as all subjects were aware
of the coming fasting period, which started on day 1 at 2400 h.
As they were only found in the presence of a GHR blocker,
one must conclude that these GHRP-6-induced changes in
insulin, glucose, and FFA levels are not modulated by the GH
system. These observations suggest that a certain degree of
GH action in peripheral target tissues, such as the pancreas,
adipose tissue, and liver, control these GHRP-6-dependent
changes in serum insulin, glucose, and FFA levels. Appar-
ently there is a delicate balance between the GH-GHR system
and the GH secretagogue (GHS)-GHS receptor (GHS-R) sys-
tem in the control of the insulin-glucose-FFA system in
healthy men, whereas blockade of the GHR unmasks tissue-
specific insulin sensitivity. This tissue-specific sensitivity re-
sults in increased lipogenesis (and therefore potentially an
increase in fat mass), whereas insulin resistance of carbohy-
drate metabolism might eventually lead to insulin resistance-
related changes, as observed in type 2 diabetes mellitus (13–
17). Strikingly, the metabolic changes observed in this study
parallel those that occur during physiological aging (18–22).
Interestingly, such changes have also been observed to a
certain degree in some studies with some other GHS (23–26).
The fact that GHRP-6 administration induces these metabolic
effects could hypothetically be explained by an up-regulation
of the GHS-R in the presence of pegvisomant (27, 28). Our
data also provide some insight in the mechanisms that might
underlie the observed reduced insulin sensitivity in both
acromegalics and GH-deficient patients, with respect to car-
bohydrate metabolism, and opposite changes in lipogenesis
and lipolysis in GHD vs. acromegaly (29–31). Apparently,
the high GH concentrations in acromegaly augment glyco-
lysis and lipolysis, and as a consequence, hyperinsulinism
develops. In conditions in which GH signaling is lacking in
peripheral tissue (e.g. GHD); however, GHS-mediated gly-
colysis increases, and hyperinsulinism develops, which, in
turn, induce lipogenesis. Unpublished observations (A. J.
van der Lely) support this delicate balance between insulin
and GH action, as a number of acromegalic patients who
were treated weekly with high dosages of 80 mg pegviso-
mant, sc, developed hypertrophy of sc adipose tissue at the
injection site. This was a reversible phenomenon, as during
the follow-up period off medication these changes in adipose
tissue quickly resolved.
The mechanisms responsible for the observed GHRP-6-
mediated increase in serum glucose and insulin concentra-
tions during GHR blockade in the nonfasting state are not
known. Strikingly, on day 1, when all subjects were also in
the nonfasting state but without the presence of GHR block-
ade, no changes in serum glucose and/or insulin concentra-
tions were observed after GHRP-6 administration. Possible
candidates for the observed metabolic changes, such as cor-
tisol, glucagon, glucagon-like peptide-1, or somatostatin, all
lack at least one of the characteristic metabolic reactions
observed in this study (increases in glucose and insulin as
well in lipogenesis). It is unlikely that glucocorticoids are
responsible for the increase in serum glucose and insulin
concentrations, because on day 4, serum cortisol and ACTH
levels decreased rapidly during the first 8 h after GHRP-6
administration, as expected on the basis of a normal diurnal
pattern (data not shown). Although the metabolic effects of
glucagon on glucose and insulin levels are the same as those
observed after GHRP-6 administration, it has strong lipolytic
activities as well (32–35). Glucagon-like peptide-1 has both
lipogenic and insulinogenic actions, but it decreases glucose
levels, as it is a powerful glucogenic factor (36). Whether the
recently discovered and first known endogenous ligand of
the GHS receptor (37) shares the observed GHRP-6-mediated
changes in metabolic parameters (and the possible subse-
592 MULLER ET AL. JCE & M † 2001
Vol. 86 † No. 2
 at Medical Library Erasmus MC on November 28, 2006 jcem.endojournals.orgDownloaded from 
quent changes in body composition) will be answered when
data on the effects of ghrelin administration become avail-
able. Finally, changes in paracrine somatostatin activity
within the pancreatic islets would either increase or decrease
insulin secretion, with opposite changes in glucose levels.
Possibly, with this study we have observed direct GHS-R-
mediated effects on glycolysis and insulin secretion.
Finally, Fig. 1 clearly shows that in the fasting groups, the
presence of pegvisomant was not significantly important for the
changes observed in glucose, insulin, and FFA levels. Appar-
ently in this situation, loss of GH action and/or a drop in IGF-I
levels seem not to be the major players in fasting-related
changes in these parameters. In the nonfasting state, however,
and in the presence of pegvisomant, a drop in free, but not total,
IGF-I was observed. However, we observed an increase in IGF-I
levels on day 2 in all subjects, which most likely was induced
by the two stimulatory tests on day 1. After day 2, total IGF-I
levels began to decrease, but this decrease did not reach the
level of significance on day 4. Other studies are necessary to rule
out confounding effects of changes in IGF-I on all noted find-
ings. The question of which item (loss of GH action or decrease
in free IGF-I concentrations) is responsible for the observed
changes in glucose, insulin, and FFA levels after injection of
GHRP-6 remains to be answered.
In conclusion, we found that under the condition of GHR
blockade, GHRP-6 has profound stimulatory effects on serum
insulin and glucose levels, which reflect a state of insulin re-
sistance. These GHRP-6-induced changes only occur in the non-
fasting state in the presence of GHR blockade. In the same
condition there is an increase in lipogenesis, which indicates
tissue-specific differential changes in insulin sensitivity that
actually could lead to undesired changes in body composition.
We also conclude that these possible effects of GHRP-6 are
GH independent, and that in man some degree of GH action
is necessary to prevent these GHRP-6-induced metabolic
changes. Moreover, we postulate that direct GHS-R-mediated
effects are involved in the induction of the metabolic alterations
as well as subsequent changes in body composition, which are
characteristic of the insulin resistance syndrome.
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